A new observational study has shown that Toujeo insulin reduced events of hypoglycemia by 33 per cent compared to other basal insulins.
Toujeo is a once-daily long-acting insulin made by Sanofi, the same company that makes Lantus.
The results of the DELIVER 2 study, which involved 1,894 people, were released during the Endocrine Society 2017 Annual Meeting in Orlando, Florida, US.
Riccardo Perfetti, who is head of Sanofi’s global diabetes medical team, said: “These results increase the body of evidence on the use of Toujeo in people with type 2 diabetes from observational studies.
“While randomised clinical trials provide the highest level of evidence, comparative data from real-world observational studies can be relevant for […] evaluating how findings from clinical trials can translate into routine clinical practice.”
The DELIVER 2 trial used data from 1,894 people with type 2 diabetes to test how effective Toujeo was during a six-month period.
Patients who switched to Toujeo had a 33 per cent reduced risk of hypoglycemia and a 48 per cent reduction in hypoglycemic events that led to a hospital visits, compared to other basal insulins.
Toujeo is also known as insulin glargine 300, and was approved as a diabetes treatment in the UK in early 2015.
Its blood sugar-lowering activity lasts beyond 24 hours when taken once a day at the same time each day.
To build on this observational study, researchers are now conducting randomised trials involving more than 4,500 people with type 2 diabetes across Europe and the US who are beginning basal insulin treatment or switching from another basal insulin.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…